Study S000705

Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02721888
Acronym: LIRA-NAFLD/LIP
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: TERMINATED
Enrollment: 127
Start: 2012-07-10
Primary completion: 2019-10-02
Lead sponsor: Centre Hospitalier Universitaire Dijon
Conditions: Type 2 Diabetes
Interventions: DRUG:Liraglutide; DRUG:MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy); BIOLOGICAL:Blood sample; OTHER:Kinetic substudy (10 patients)
Results posted: FALSE

Registered primary outcomes

Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) production rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Very Low Density Lipoprotein 1 (VLDL1) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Very Low Density Lipoprotein 2 (VLDL2) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Intermediate Density Lipoprotein (IDL) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on Low Density Lipoprotein (LDL) apolipoprotein B (apoB) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]
Effects of liraglutide on High Density Lipoprotein (HDL) apolipoprotein A1 (apoA1) fractional catabolic rate [Before and after 6 month-treatment with liraglutide (1.2 mg/day)]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016567	Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes. Denimal D, Cardiovascular diabetology	2023	Other trial	PMID 37143040 DOI	cites ClinicalTrials.gov:NCT02721888; registry reference DERIVED:37143040
R0020322	Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression. Vergès B, Diabetes care	2021	Preclinical	PMID 33531418 DOI	cites ClinicalTrials.gov:NCT02721888; registry reference DERIVED:33531418
R0024693	Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus. Vergès B, Arteriosclerosis, thrombosis, and vascular biology	2018	Other trial	PMID 30026275 DOI	cites ClinicalTrials.gov:NCT02721888; registry reference RESULT:30026275